Hangzhou Minsheng Healthcare Co Ltd

Minsheng Health announced that the company has received the Drug Supplementary Application Approval Notice for Glucosamine Sulfate Capsules issued by the National Medical Products Administration. The drug is indicated for primary and secondary osteoarthritis. The company stated that obtaining this drug approval will help enrich its product portfolio and enhance market competitiveness. The company also cautioned that pharmaceutical sales are susceptible to industry policy changes, market competition, and other factors, and therefore involve uncertainty.

Minsheng Health released its 2026 interim report on August 28, 2026. During the reporting period, the company achieved total operating revenue of 535 million yuan and net profit attributable to the parent company of 83.3943 million yuan. Net cash inflow from operating activities was 137 million yuan, a decrease of 5.2026 million yuan compared with the same period last year, down 3.67 percent year on year. The company's asset-liability ratio was 17.68 percent, up 2.13 percentage points from the previous quarter and up 3.00 percentage points from the same period last year. Gross margin was 55.17 percent, down 2.61 percentage points from the previous quarter. Return on equity was 5.17 percent, down 0.05 percentage points from the same period last year. Diluted earnings per share were 0.23 yuan. Total asset turnover was 0.26 times, and inventory turnover was 2.79 times. The number of shareholders was 17,600, and the top ten shareholders held 255 million shares, accounting for 71.59 percent of total share capital.

Minsheng Health announced that as of July 31, 2026, it had repurchased 2.32 million shares, representing 0.65% of total share capital, at a price range of 11.77 yuan to 15.67 yuan per share, with a total buyback amount of 34.15 million yuan. In the first quarter of 2026, the company achieved revenue of 317 million yuan and net profit attributable to the parent of 62.78 million yuan.